[{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"19c4df63-c1d0-4fe1-a179-ba050e9a7b85","acronym":"","url":"https://clinicaltrials.gov/study/NCT04955938","created_at":"2021-07-09T12:57:16.797Z","updated_at":"2024-07-02T16:35:49.331Z","phase":"Phase 1","brief_title":"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","source_id_and_acronym":"NCT04955938","lead_sponsor":"University of Chicago","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inrebic (fedratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-04-28"}]